Hallmark pathways significantly enriched in the discovery dataset among cluster 1 anti–IL-6 responders and in all siltuximab nonresponders
| Pathway . | Nominal P value . | FDR q value . |
|---|---|---|
| Enriched pathways in cluster 1 siltuximab responders vs HDs | ||
| TNFα signaling via NF-κB | .004 | 0.090 |
| Estrogen response early | .013 | 0.137 |
| IFN-γ response | .033 | 0.149 |
| Allograft rejection signature | .033 | 0.167 |
| IL-6-JAK STAT3 signaling | .020 | 0.184 |
| Enriched pathways in siltuximab nonresponders vs HDs | ||
| KRAS signaling up | .029 | 0.118 |
| IL-6-JAK STAT3 signaling | .031 | 0.144 |
| TNFα signaling via NF-κB | .006 | 0.173 |
| Allograft rejection signature | .043 | 0.177 |
| IL2 STAT5 signaling | .018 | 0.179 |
| Pathway . | Nominal P value . | FDR q value . |
|---|---|---|
| Enriched pathways in cluster 1 siltuximab responders vs HDs | ||
| TNFα signaling via NF-κB | .004 | 0.090 |
| Estrogen response early | .013 | 0.137 |
| IFN-γ response | .033 | 0.149 |
| Allograft rejection signature | .033 | 0.167 |
| IL-6-JAK STAT3 signaling | .020 | 0.184 |
| Enriched pathways in siltuximab nonresponders vs HDs | ||
| KRAS signaling up | .029 | 0.118 |
| IL-6-JAK STAT3 signaling | .031 | 0.144 |
| TNFα signaling via NF-κB | .006 | 0.173 |
| Allograft rejection signature | .043 | 0.177 |
| IL2 STAT5 signaling | .018 | 0.179 |